Abstract 5555
Background
In RAS wild type metastatic colorectal cancer patients (pts), high tumor expression of microRNA miR-31-3p and miR-31-5p has been associated with poorer benefit of anti-EGFR therapy. miR-31-3p expression has been shown to be predictive of treatment effect in the FIRE-3 trial. The PETACC-8 phase III trial assessed the efficacy of cetux addition to FOLFOX compared to FOLFOX only in pts with resected stage III colon cancer (CC). The primary end point was negative, but a trend towards benefit of cetux on disease free survival (DFS) was observed in pts with RAS/BRAF wild type (WT) tumors. The current study aimed at assessing miR-31-3p and 5p tumor levels as prognostic and predictive biomarkers of adjuvant cetux benefit in these pts.
Methods
miR-31-3p and 5p levels were measured by RT-qPCR from 477 WT pts tumor RNA. The primary objective was to demonstrate a benefit of cetux on DFS for low miR-31-3p expressers. Cox regression model was used for univariate and multivariate analyses. Optimal cut-off values for low and high expressers were determined post hoc.
Results
In the studied population, cetux benefit was significant for DFS (HR = 0.71 [0.50;1.00] p = 0.05) but not for Overall Survival (OS) (HR = 0.79 [0.53;1.18] p = 0.25). Expression of miR-31-3p and miR-31-5p were highly correlated (R > 0.9). Higher miR-31-3p and 5p expression were associated with shorter DFS and OS (p < 0.01). Pts with low miR-31-3p levels (n = 218/435, 50%) had a non-significant benefit from cetux on DFS (HR 0.61 [0.33; 1.11] p = 0.10) and OS (HR = 0.67 [0.33; 1.35] p = 0.26). Pts with low miR-31-5p levels (n = 233/477, 49%) benefited from cetux on DFS (HR = 0.46 [0.25; 0.84] p = 0.01) and OS (HR = 0.50 [0.25; 0.99], p = 0.047) whereas high expressers did not (DFS: HR = 0.87 [0.56; 1.34] ; OS: HR = 1.01 [0.61; 1.67]). miR-31-5p was predictive of treatment effect on DFS at the 10% level (interaction tests: p = 0.09 for DFS and p = 0.103 for OS). Results were still significant after adjustment for clinical covariates.
Conclusions
In pts with resected stage III WT CC, miR-31-3p and 5p were prognostic of DFS and OS. Pts with low miR-31 expression benefited from cetux addition to FOLFOX for adjuvant therapy, and miR-31-5p was predictive of cetux efficacy.
Clinical trial identification
NCT03362684.
Legal entity responsible for the study
IntegraGen SA.
Funding
IntegraGen.
Editorial Acknowledgement
Disclosure
Y. Gaston Mathe: Ex employee: IntegraGen. S. Martin-Lannerée, C. Vazart, K. Fontaine: Employee: IntegraGen. A. Caumont, F. Montestruc: Consultant: IntegraGen. J. Taieb: Honoraria: Lilly, Celgene, Servier, Amgen, Roche, Merck, Sirtex, Sanofi. P. Laurent-Puig: Honoraria: IntegraGen, Merck-Serono, Amgen, Boehringer-Ingelheim, Roche, Lilly, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract